Hypothesis: Restoring NAD+ alone normalizes the lactate‑to‑pyruvate redox ratio but fails to suppress HIF‑1α‑driven transcription once pseudohypoxia becomes entrenched because HIF‑1α target genes generate metabolites that inhibit prolyl hydroxylases independently of NAD+/SIRT1/VHL signaling. Consequently, functional aging improvements require NAD+ repletion timed to the endogenous NAD+ peak plus pharmacological inhibition of HIF‑1α activity.

Background: Declining nuclear NAD+ reduces SIRT1 deacetylase activity, leading to VHL loss and HIF‑1α stabilization under normoxia, creating a pseudohypoxic state that disrupts nuclear‑mitochondrial communication1. NAD+ repletion with nicotinamide riboside (NR) reverses senescence markers in human mesenchymal stem cells2 and plasma NAD+ falls steeply with age3. Cardiac NAD+ also shows dampened circadian oscillations, suggesting that mistimed NR dosing may miss the window of maximal SIRT1 activation4. While NAD+ depletion predisposes to chronic disease5, human trials show limited functional benefits despite elevated NAD+.

Mechanistic extension: HIF‑1α induces pyruvate dehydrogenase kinase 1 (PDK1) and suppresses SDHA, causing succinate accumulation. Succinate competitively inhibits prolyl hydroxylase domain (PHD) enzymes, stabilizing HIF‑1α even when VHL is present and NAD+ is restored. This creates a redox‑independent lock on HIF‑1α that NR cannot break. The lactate‑to‑pyruvate ratio reflects cytosolic NAD+/NADH but does not capture succinate‑mediated PHD inhibition, explaining why NR may normalize the ratio without reducing HIF‑1α target expression.

Testable prediction: In older adults, NR administered at the individual circadian NAD+ peak will normalize lactate‑to‑pyruvate ratio but will not significantly decrease HIF‑1α target gene expression (e.g., GLUT1, PDK1, VEGF) or improve functional outcomes (6‑min walk test, grip strength). Adding a HIF‑1α inhibitor (e.g., PX‑478) delivered at the same time will suppress HIF‑1α transcription, reduce succinate levels, and yield greater functional gains than NR alone.

Study design: Randomized, double‑blind, crossover trial (n=60, aged 65‑80). Three 8‑week intervals separated by 4‑week washout: (1) placebo, (2) NR (500 mg) taken at each participant’s NAD+ peak (determined via salivary NAD+ circadian profiling), (3) NR + HIF‑1α inhibitor (PX‑478, 50 mg) at the same timing. Primary endpoints: change in lactate‑to‑pyruvate ratio in plasma, HIF‑1α target gene mRNA in peripheral blood mononuclear cells, and composite physical performance score. Secondary: circulating succinate, serum inflammatory cytokines, and quality‑of‑life questionnaires.

Falsifiability: If NR alone significantly lowers HIF‑1α target expression and improves function to the same extent as NR + HIF‑1α inhibitor, the hypothesis is falsified. Conversely, if NR + HIF‑1α inhibitor shows superior suppression of HIF‑1α targets and functional improvement while NR alone does not, the hypothesis is supported, indicating that entrenched pseudohypoxia requires concurrent HIF‑1α blockade beyond NAD+ repletion.